Learning to walk
Challenges for spinal muscular atrophy clinical trials
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Spinal muscular atrophy (SMA) is a genetically determined neuronopathy and usually presents in childhood. SMA has a broad range of phenotypes: severe early infancy onset (type I, Werdnig-Hoffman disease, non-sitters), later infancy onset, intermediate variety (type II, sitters, non-walkers), and childhood to adulthood onset (type III, Kugelberg-Welander, walkers).1,2 In addition to progressive limb and truncal weakness, dysphagia, aspiration, and respiratory insufficiency are predictable life-threatening comorbidities of the infantile type I and II forms.3 As yet, no effective drug therapy has been found for human SMA.
Advances in molecular genetics led to the discovery of the causative mutation in the Survival Motor Neuron (SMN) 1 gene and elucidation of the rescue of an otherwise lethal condition by a nearly identical homologue gene, SMN2.4 The number of copies of this SMN2 gene is inversely associated with disease severity, and this gene dosing observation has led to treatment strategies targeting SMN2.5 These strategies for SMA include induction of SMN2 gene expression, modulation of splicing of SMN2-derived transcripts, and stabilization …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.